FDA Alters Carcinogenicity Testing of Compounds Used in Food Animals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

ROCKVILLE, Md-The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

ROCKVILLE, Md—The FDA has amended its regulations for testing the carcinogenicity of compounds used in food-producing animals to eliminate the specific requirement for “oral, chronic, dose-response studies.” The new wording states that bioassays “must be designed to assess carcinogenicity and to determine the quantitative aspects of any carcinogenic response.”

When the existing regulation was issued, chronic studies were the standard. However, advances in carcinogenicity modeling have changed scientists’ views. For example, many researchers now agree that a chronic study “may not measure the appropriate time point necessary to assess carcinogenicity for some compounds,” the FDA said.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content